Company intelligence / Profile preview

EndoValve

King of Prussia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

EndoValve was a medical technology company focused on developing minimally invasive solutions for structural heart disease. The company's primary innovation was a transcatheter mitral valve replacement (TMVR) system designed to treat patients with mitral regurgitation who are at high risk for traditional open-heart surgery. Its technology aimed to provide a percutaneous alternative for valve replacement, utilizing a unique anchoring mechanism. In 2011, the company was acquired by Edwards Lifesciences to bolster their transcatheter valve portfolio.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on EndoValve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoValve.

Explore the full profile